v3.26.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2026
Segment Information  
Schedule of Segment information

When evaluating the Company’s financial performance, the CODM regularly reviews the following expense categories that comprise net loss. The table below sets forth the Company’s segment information as reviewed by the CODM:

Three Months Ended

March 31, 

  ​ ​ ​

2026

  ​ ​ ​

2025

Program expenses related to clinical-stage product candidates

$

(15,580,338)

$

(4,217,214)

Program expenses related to preclinical and discovery programs

(196,994)

(30,600)

Program expenses related to clinical manufacturing candidates

(270,830)

-

Personnel-related expenses (including stock-based compensation)

(1,272,579)

(1,397,874)

General and administrative professional and consultant fees

(490,577)

(444,865)

Other segment items1

(200,864)

(192,128)

Interest income

137,800

187,612

Other non-cash income (expense) items2

268,000

558,000

Net Loss

$

(17,606,382)

$

(5,537,069)

1 Other segment items included in net loss include insurance expenses, rent expense, information technology expenses, listing/printing fees, warrant commissions and other miscellaneous expenses.

2 Other non-cash income (expense) items include the change in fair value of our liability classified warrants.